Full-ring Positron Emission Tomography Research Articles

Positron Emission Tomography of Not-Full-Ring Sensors Arrangement: Simulation and Verification for Internal Imaging of Hydraulic Cylinder

The research goal of this article is to imaging the oil distribution in landing gear hydraulic cylinder by Positron Emission Tomography(PET). Considering the flexibility and commercial cost for automation testing, two kinds of Not-Full-Ring sensors arrangement, Uniform-arrangement and Bilateral-arrangement, are proposed. The Full-Ring PET is used as the contrast template of imaging. Firstly, GATE 7.1 is used as the Monte Carlo simulation platform to simulate the sensors arrangement of the two Not-Full-Ring schemes. The results of scattering fraction, sensitivity and photon energy distribution were used to evaluate the feasibility of the two schemes. Then, a set of verification device with rotating platform and variable sensing diameter is constructed. The two kinds of Not-Full-Ring sensors arrangements were verified through the verification device. By imaging the hydraulic oil in the hydraulic cylinder, the results were evaluated and compared by using Signal Noise Ratio(SNR). According to the simulation and verification results, Not-Full-Ring scheme is feasible for imaging the liquid distribution in the hydraulic cavity. Uniform- arrangement has a more better imaging performance than Bilateral-arrangement. Such sensors arrangement scheme is not only suitable for this research, but also suitable for other PET imaging applications which need to consider the flexibility and commercial cost.

Offline imaging of positron emitters induced by therapeutic helium, carbon and oxygen ion beams with a full-ring PET/CT scanner: experiments in reference targets

In vivo verification of light ion therapy based on positron-emission tomography (PET) imaging of irradiation induced patient activation relies on activity predictions from Monte-Carlo (MC) or analytical computational engines for comparison to the measurements. In order to achieve the necessary accuracy, experimental data are indispensable for the validation of the calculation models. For this we irradiated thick reference targets with mono-energetic helium, carbon and oxygen ion beams and measured the resulting material activation offline with a commercial full-ring PET/CT scanner located nearby the treatment room.Acquired PET data were analysed over time to separate the activity contribution of different radionuclides. Determined production yields were compared to published findings obtained from in-beam activation measurements with a limited-angle double-head PET camera. In addition, we investigated the time-dependence of the measured radionuclide-specific contributions and of the distal activity range, as well as the lateral spread of the activity signal as a function of beam penetration depth.We present radionuclide-specific depth-resolved activity distributions and production yields for the radionuclides , and , dominating irradiation-induced patient activation. We observe systematically lower production yields with a ratio between the dual-head and our full-ring PET measurements of, on average, 1.7 and 1.3 for the oxygen and carbon beam irradiations, and 1.7 (2.1) for the high (low) energy helium beam irradiations. Findings on the temporal development of the activity range confirm the expectation, with the oxygen beam induced signal being the most sensitive scenario.The experimental data reported in this work, acquired with a state-of-the-art full ring PET scanner, provide a comprehensive and consistent basis for the benchmarking of PET signal calculation engines. In particular, they can support a fine-tuning of the underlying physics models used by the respective implementation and therefore improve the accuracy of PET-based therapy verifications at current and future treatment facilities.

A simulation study of a dual-plate in-room PET system for dose verification in carbon ion therapy

During carbon ion therapy, lots of positron emitters such as 11C, 15O, 10C are generated in irradiated tissues by nuclear reactions, and can be used to track the carbon beam in the tissue by a positron emission tomography (PET) scanner. In this study, an dual-plate in-room PET scanner has been designed and evaluated based on the GATE simulation platform to monitor patient dose in carbon ion therapy. The dual-plate PET is designed to avoid interference with the carbon beamline and with patient positioning. Its performance was compared with that of four-head and full-ring PET scanners. The dual-plate, four-head and full-ring PET scanners consisted of 30, 60, 60 detector modules, respectively, with a 36 cm distance between directly opposite detector modules for dose deposition measurements. Each detector module consisted of a 24×24 array of 2 mm×2 mm×18 mm LYSO pixels coupled to a Hamamatsu H8500 PMT. To estimate the production yield of positron emitters, a 10 cm×15 cm×15 cm cuboid PMMA phantom was irradiated with 172, 200, 250 MeV/u 12C beams. 3D images of the activity distribution measured by the three types of scanner are produced by an iterative reconstruction algorithm. By comparing the longitudinal profile of positron emitters along the carbon beam path, it is indicated that use of the dual-plate PET scanner is feasible for monitoring the dose distribution in carbon ion therapy.

TOF capability evaluation on a panel PET for human body imaging

Due to its unique structure, parallel panel configuration may lead to novel applications for positron emission tomography (PET). The major challenge of panel PET imaging is the limited angle problem, to which the time-of-flight (TOF) information seems to be a promising solution. This work investigated the required TOF capability of a panel PET design, which has a feasible size of field of view (FOV) for human torso. Such a system's corresponding angular coverage can vary from 70 to 102 degrees. The recovery ability of small lesions was assessed, and the contrast recovery coefficient (CRC) and signal-to-noise ratio (SNR) were analyzed, with a full ring PET as the benchmark system. We also varied the timing resolution and the distance between panels, to evaluate their impacts on image quality. Encouraging results were obtained in simulation study. Distortions and artifacts caused by the limited angular coverage were greatly reduced with timing resolutions better than 300 ps. The recovery ability of small lesions in most part of FOV was desirable. Meanwhile, varying panel distance in the range of 25 to 45 cm seemed to have trivial influence, when timing resolution was fixed at 300 ps. That means that such changes of panel distance might not affect the requirement on TOF capability, allowing more flexibility in panel PET's design and applications.

A small animal PET based on GAPDs and charge signal transmission approach for hybrid PET-MR imaging

Positron emission tomography (PET) employing Geiger-mode avalanche photodiodes (GAPDs) and charge signal transmission approach was developed for small animal imaging. Animal PET contained 16 LYSO and GAPD detector modules that were arranged in a 70 mm diameter ring with an axial field of view of 13 mm. The GAPDs charge output signals were transmitted to a preamplifier located remotely using 300 cm flexible flat cables. The position decoder circuits (PDCs) were used to multiplex the PET signals from 256 to 4 channels. The outputs of the PDCs were digitized and further-processed in the data acquisition unit. The cross-compatibilities of the PET detectors and MRI were assessed outside and inside the MRI. Experimental studies of the developed full ring PET were performed to examine the spatial resolution and sensitivity. Phantom and mouse images were acquired to examine the imaging performance. The mean energy and time resolution of the PET detector were 17.6% and 1.5 ns, respectively. No obvious degradation on PET and MRI was observed during simultaneous PET-MRI data acquisition. The measured spatial resolution and sensitivity at the CFOV were 2.8 mm and 0.7%, respectively. In addition, a 3 mm diameter line source was clearly resolved in the hot-sphere phantom images. The reconstructed transaxial PET images of the mouse brain and tumor displaying the glucose metabolism patterns were imaged well. These results demonstrate GAPD and the charge signal transmission approach can allow the development of high performance small animal PET with improved MR compatibility.

Multimodal virtual bronchoscopy using PET/CT images

Objective: To demonstrate the possibilities, advantages and limitations of virtual bronchoscopy using data sets from positron emission tomography (PET) and computed tomography (CT).Materials and Methods: Eight consecutive patients with non-small cell lung cancer (NSCLC) underwent PET/CT. PET was performed with a glucose analog, 2-[fluorine-18]-fluoro-2-deoxy-D-glucose (18F-FDG), using a state-of-the-art full-ring Pico-3D PET scanner. CT was performed with a venous-dominant contrast-enhanced phase using a 16-slice CT scanner. The tracheobronchial system was segmented using the CT data set with an interactive threshold interval volume-growing segmentation algorithm. The primary tumors and lymph node metastases were segmented for virtual CT-bronchoscopy using the CT data set and for virtual hybrid bronchoscopy using the PET/CT data set. The structures of interest were visualized with a color-coded shaded-surface rendering method.Results: The use of CT and virtual CT-bronchoscopy primarily facilitates visualization of the anatomical details of the tracheobronchial system and detection of anatomical/morphologic structural changes caused by disease. PET/CT and virtual hybrid bronchoscopy, or virtual PET/CT-bronchoscopy, give superior results to virtual CT-bronchoscopy because the hybrid bronchoscopy uses both the CT information and the molecular/metabolic information about the disease obtained from PET.Conclusions: PET/CT imaging has proven to be a highly valuable oncological diagnostic modality. Virtual hybrid bronchoscopy can be performed using a low-dose CT scan or diagnostic CT. However, it is expected to improve diagnostic accuracy in identification and characterization of malignancies, verification of infections, and differentiation of viable tumor tissue from atelectases and scar tissue, as well as assessment of tumor staging and therapeutic response, and detection of early stage recurrences that are not detectable or are liable to be misjudged using virtual CT-bronchoscopy. It could also be useful as a screening examination method for patients with suspected endobronchial malignancy. Virtual hybrid bronchoscopy with a transparent color-coded shaded-surface rendering model offers a useful alternative to fiberoptic bronchoscopy, and is particularly promising for patients for whom fiberoptic bronchoscopy is not feasible, contraindicated or refused.

Comparison of 18F-FDG and 67Ga-citrate in sarcoidosis imaging

(67)Ga citrate has been used long and successfully to diagnose and stage sarcoidosis. (18)F-fluorodeoxyglucose ((18)F-FDG) has been suggested as a positron emission tomography (PET) tracer for sarcoidosis imaging. This study aimed to analyze possible advantages of (18)F-FDG-PET over (67)Ga citrate scintigraphy during the primary assessment of patients with sarcoidosis. Twenty-four patients (11 men, 13 women, aged 52 years +/-12.4) with histologically proven sarcoidosis were investigated with (18)F-FDG and (67)Ga citrate. Equipment included a full-ring PET scanner (ECAT EXACT HR+, Siemens/CTI, Knoxville TN, USA) and a double-headed gamma camera (ECAM, Siemens, Illinois, USA) for scintigraphy. The mean time difference between the two studies was 6.5 days (range: 5-8 days). There was a significant difference in the detection of pulmonary and nonpulmonary sarcoidosis lesions between planar (67)Ga citrate scans and (18)F-FDG-PET images (<0.0021). A total of 64 lesions were detected with (67)Ga citrate scans in the thorax and elsewhere with a mean of 2.6 lesions (4%) per patient, while 85 lesions were found with (18)F-FDG-PET, with a mean of 3.5 lesions (4.1%) per patient. There was complete agreement between (18)F-FDG and (67)Ga citrate in thoracic manifestations in four (16.6%) patients, and in non-thoracic manifestations in five (20.8%) patients. The interobserver variability showed a kappa value of 0.79. (67)Ga citrate and (18)F-FDG are useful tracers for diagnostic evaluation of thoracic sarcoidosis. (18)F-FDG seems to be more suitable for imaging the mediastinum, the bi-hilar lymph nodes, the posterior regions of the lungs and non-thoracic lesions. Further prospective studies are needed to clarify the role of both tracers in early diagnosis and staging of sarcoidosis, and to resolve questions concerning medical treatment and follow-up.

A prospective multi-centre study of the value of FDG-PET as part of a structured diagnostic protocol in patients with fever of unknown origin

Since (18)F-fluorodeoxyglucose (FDG) accumulates in neoplastic cells and in activated inflammatory cells, positron emission tomography (PET) with FDG could be valuable in diagnosing patients with fever of unknown origin (FUO). The aim of this study was to validate the use of FDG-PET as part of a structured diagnostic protocol in the general patient population with FUO. From December 2003 to July 2005, 70 patients with FUO were recruited from one university hospital (n=38) and five community hospitals (n=32). A structured diagnostic protocol including FDG-PET was used. A dedicated, full-ring PET scanner was used for data acquisition. FDG-PET scans were interpreted by two staff members of the department of nuclear medicine without further clinical information. The final clinical diagnosis was used for comparison with the FDG-PET results. Of all scans, 33% were clinically helpful. The contribution of FDG-PET to the final diagnosis did not differ significantly between patients diagnosed in the university hospital and patients diagnosed in the community hospitals. FDG-PET contributed significantly more often to the final diagnosis in patients with continuous fever than in patients with periodic fever. FDG-PET was not helpful in any of the patients with normal erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). FDG-PET is a valuable imaging technique as part of a diagnostic protocol in the general patient population with FUO and a raised ESR or CRP.

Potential Time Benefit in the Assessment of Recurrent Rat Rhabdomyosarcoma Using Positron Emission Tomography (PET) with 18Fluorodeoxyglucose Depends on Therapy-Specific Growth Delay

To correlate the potential time benefit of (18)F-fluorodeoxyglucose positron emission tomography ((18)FDG-PET) in terms of early detection of recurrences of subcutaneously growing R1H tumors with therapy-specific parameters of recurrent tumor. Twelve, eleven, and seven recurrences were followed after fractionated radiotherapy, surgery, and chemotherapy for 6 months, respectively, and (18)FDG-PET was performed weekly using a conventional full-ring whole-body PET scanner. By comparing PET results and actual tumor volume, the time benefit of (18)FDG-PET in detection of recurrent tumors of 0.1, 0.2, and 0.5 cm(3) was determined for the different treatment strategies. A significant time benefit of (18)FDG-PET of 26.9 days and 67 days was solely determined for recurrences after radiotherapy of 0.2 cm(3) and 0.5 cm(3), respectively. The potential time benefit showed a strong correlation with growth delay, which was increased after radiotherapy due to a pronounced tumor-bed effect. The potential time benefit of (18)FDG-PET is strongly determined by the growth kinetics of the recurrence. A tumor-bed effect, which is a phenomenon solely seen after radiotherapy, favors early detection by (18)FDG-PET. The experimental data, clinical experience and theoretical consideration all indicate a noticeable benefit of (18)FDG-PET especially after radiotherapeutic treatment.

Evaluation of pulmonary nodules: comparison of a prototype dual crystal (LSO/NAI) dual head coincidence camera and full ring positron emission tomography (PET)

Purpose: To determine the concordance of a prototype dual head coincidence camera (LSO-PS) and full ring PET (BGO-PET) using 18F-fluorodeoxyglucose (FDG) in the evaluation of pulmonary nodules (PNs). Materials and methods: Patients referred for evaluation of ≤3 PNs (≤3 cm diameter) were prospectively studied on the same day with both BGO-PET and LSO-PS. Imaging was performed at 60 and 120 min after injection of 370 MBq FDG, respectively. Images were independently interpreted by four observers with each observer blinded to the other modality for the same patient. Lesions were scored in terms of relative intensity versus background. Non-attenuation corrected (nonAC) BGO-PET was used as the reference test. Results: Forty-seven patients with 54 PNs (mean diameter 1.7 cm, S.D. 0.7) were included. Twelve nodules were in the ≤1.0 cm – 27 in the 1.1–2.0 cm – and 15 in the 2.1–3.0 cm range. Interobserver agreement was similar for both FDG imaging modalities. Using a sensitive assessment strategy with LSO-PS (≥ faint intensity deemed positive), there was a 97% (38/39, 95%CI 87–100%) concordance with BGO-PET and one false positive case with LSO-PS. Conservative reading (moderate or intense intensity deemed positive) resulted in a 92% (36/39, 95%CI 80–97%) concordance with BGO-PET, without false positives. The only lesion missed by LSO-PS using both assessment strategies involved a nodule 1.5 cm diameter that demonstrated moderate increased FDG uptake on BGO-PET. Conclusion: Depending on the test positivity criteria, LSO-PS demonstrates a high concordance (92–97%) with nonAC BGO-PET for the characterization of pulmonary nodules.

RatCAP: miniaturized head-mounted PET for conscious rodent brain imaging

Anesthesia is currently required for positron emission tomography (PET) studies of the animal brain in order to eliminate motion artifacts. However, anesthesia profoundly affects the neurological state of the animal, complicating the interpretation of PET data. Furthermore, it precludes the use of PET to study the brain during normal behavior. The rat conscious animal PET tomograph (RatCAP) is designed to eliminate the need for anesthesia in rat brain studies. It is a miniaturized full-ring PET scanner that is attached directly to the head, imaging nearly the entire brain. RatCAP utilizes arrays of 2 mm /spl times/ 2 mm LSO crystals coupled to matching avalanche photodiode arrays, which are in turn read out by full custom integrated circuits. Principal challenges have been addressed considering the physical constraints on size, weight, and heat generation in addition to the usual requirements of small-animal PET, such as high spatial resolution in the presence of parallax error. A partial prototype has been constructed and preliminary measurements and optimization completed. Realistic Monte Carlo simulations have also been carried out to optimize system performance, which is predicted to be competitive with existing microPET systems.

The suitability of gamma camera coincidence systems for nitrogen 13–labeled ammonia myocardial perfusion imaging: a quantitative comparison with full-ring PET

Background The aim of this study was to examine the quality of nitrogen 13–labeled ammonia (NH 3) perfusion data from coincidence-capable gamma camera positron emission tomography (GC-PET) systems compared with that from full-ring positron emission tomography (FR-PET). Methods and results The performance parameters of the GC-PET system were examined and found adequate for imaging at the activity levels used clinically. We studied 15 patients who underwent stress and rest N-13–labeled NH 3 perfusion imaging on FR-PET and GC-PET systems. Quantitative analysis of perfusion values showed that GC-PET uptake was significantly lower than FR-PET uptake in 67.6% of segments. Bland-Altman analysis showed that the mean difference between FR-PET and GC-PET values was from 5.3% to 5.9%. Stress FR-PET identified 49 segments as having impaired perfusion, 46 (93.9%) of which were also identified by GC-PET. Fifty-six additional segments were identified as abnormal by GC-PET. These findings indicated a general overestimation of defect size on GC-PET. Analysis of the degree of perfusion reduction also found that GC-PET tended to overestimate defect contrast. These findings are similar to those previously found by workers examining fluorine 18–fluorodeoxyglucose uptake by both techniques. Conclusions Good concordance was shown between GC-PET and FR-PET systems for N-13–labeled NH 3 perfusion imaging, although further work is required to optimize the technique.

Initial clinical experience using a new integrated in-line PET/CT system.

Whole-body positron emission tomography (PET) with F-fluorodeoxyglucose (FDG) has proven to be a very effective staging imaging modality in manymalignant tumours, particularly in lung cancer, malignant melanoma, lymphoma, colorectal cancer and head and neck tumours [1–7]. Since PET images have a fairly high resolution (,6 mm), even small lesions with an increased FDG uptake can be detected. This represents a critical advantage of PET over the conventional cross-sectional imaging modalities CT and MRI. PET can be used to identify tumour tissue on the basis of FDG uptake, rather than on the basis of morphological appearance or size, and thus also in lesions with a size less than 1 cm. Unfortunately, FDG–PET provides little anatomical information, and therefore it is sometimes difficult to determine where the lesions detected are located and what they represent. It is important for the surgeon to know precisely where lesions are located, especially for small tumours. Currently, comparison and juxtaposition of PET images and CT images serves to define the localization of the lesions. Owing to the different image slice thickness, the different positioning of the patient during the two examinations and the different states of nutrition, i.e. fasting for 4 h prior to FDG–PET, it is often very difficult and time consuming to match the images for exact anatomical localization. Image co-registration has been used to overcome these problems [8]. It has been recognized that proper image co-registration is rather difficult for whole-body examinations with separate scanners. For identical patient positioning during PET and CT scanning, special ‘‘cast forming’’ vacuum mattresses or other immobilization methods should be used. However, patients frequently find these methods of immobilization uncomfortable. Logistic problems also limit the use of image co-registration of PET and CT with separate scanners. Scheduling problems arise when performing the two examinations one after the other. These limitations restrict image co-registration with separate scanners to individual cases. In our experience, the exact localization of lesions is often not possible when juxtaposing PET and CT images. Examinations had to be repeated for exact image co-registration. As a result, image co-registration with separate scanners has never become routine in our practice. To overcome the problems related to software fusion, various prototype systems combining molecular and morphologic imaging have been developed. Hasegawa and colleagues proposed an integrated SPECT/CT scanner [9], and in 1999 Townsend and his colleagues at the University of Pittsburgh presented a prototype integrated PET/CT scanner by combining a CT scanner and a partial ring, rotating PET scanner in a single gantry [10, 11]. Such systems are attractive not only because of the ‘‘hardware’’ image coregistration capabilities but also because the CT data can be used to correct PET scans for patient self-absorption of the PET emission rays. This decreases the acquisition time for the correcting attenuation scans by an order of magnitude compared with the conventional techniques used in PET for this purpose, and decreases the overall imaging time by up to 30% depending on the CT system used. In March 2001, the first clinical integrated PET/ CT device (Discovery LS, GE Medical Systems, Milwaukee, USA) was installed at the University Hospital of Zurich in Switzerland. This novel inline system consists of a dedicated high resolution/ high sensitivity full-ring PET scanner (Advance Nxi) and a very fast high-end multi-detector spiral CT scanner (Light Speed Plus). The axes of both systems are mechanically aligned so that simple translation of the patient table by 60 cm moves the patient from the CT into the PET gantry. The resulting PET and CT images are ‘‘hardware’’ coregistered to an accuracy in the range of 1 mm. Data acquisition in the combined system is as follows. At 45–55 min post-injection of FDG and after bladder emptying a multidetector computed tomography scan is performed from the pelvic floor to the head (scan length, 86.7 cm) and normal end-expiration. Immediately after CT scanning, a PET emission scan is obtained covering the identical axial field of view using six PET fields of view. The acquisition time is 4 min at each table position. With this protocol it is The British Journal of Radiology, 75 (2002), S36–S38 E 2002 The British Institute of Radiology

Positron emission tomography: establishing priorities for health technology assessment.

Positron emission tomography (PET) is an expensive diagnostic imaging technology. Despite the long history of PET development, the costs and effectiveness of its use in routine clinical practice remain unknown. Against this background of uncertainty regarding the clinical role of PET, the UK Standing Group on Health Technology requested a review of its current and potential role which would enable research priorities in this area to be established. This 3-month project had two explicit objectives: (1) to review the state of knowledge regarding the clinical applications of PET; (2) to determine the key health technology assessment (HTA) research questions relating to the use of PET in the UK. A literature review to ascertain the state of knowledge regarding the clinical applications of PET and a three-round Delphi study to inform the key HTA research questions relating to the use of PET in the UK were undertaken. The results of an earlier systematic review, published by the Veteran's Health Administration (VHA) in the USA in 1996, were used as the starting point for the literature review. The VHA review was updated and extended by means of MEDLINE and Cochrane Library database searches. Participants in the Delphi study were selected by discussion with five individuals in the UK with an interest in, and awareness of, developments in PET. As a result of their suggestions, 43 individuals were initially invited to participate, of whom two did not feel appropriately qualified. Questionnaires were sent by facsimile to all invited participants, who were asked to return the completed forms by facsimile within a week. The content and structure of the Delphi study was informed by the results of the literature review. The responses and comments of the participants were a major source of information for this report. Clinical applications for PET have been advocated in three broad disease groups: oncology, cardiology and neuropsychiatric disorders. There are currently four PET modalities that need to be considered when assessing its potential clinical role in the UK: full ring PET scanners operating in two or three dimensions (available at five sites); partial ring rotating PET scanners (one currently operating in the UK); coincidence imaging with modified gamma camera technology; and high-energy collimator imaging of 511 keV photons with modified gamma camera technology. There is a paucity of available evidence relating to the cost-effectiveness of the various PET modalities in all of the clinical indications for which the technology is currently being advocated. In addition, many existing reports on the diagnostic accuracy of PET are limited because they are liable to bias and often relate only to very small patient numbers. The results of the Delphi study indicated that the four most important research priorities for the NHS, in descending order of their importance, are: (1) the relative cost-effectiveness of (a) full ring PET, (b) gamma camera PET using coincidence imaging and (c) existing diagnostic strategies to determine staging prior to operative intervention for lung cancer; (2) partial ring PET compared with full ring PET in oncology (3) the relative cost-effectiveness of (a) full ring PET, (b) gamma camera PET using coincidence imaging and (c) existing diagnostic strategies to stage and monitor treatment response in breast cancer; (4) the relative cost-effectiveness of (a) gamma camera PET using coincidence imaging and (b) 511 keV collimated positron imaging for assessing myocardial viability when selecting patients for revascularisation surgery. Vignettes describing each of the research priorities are provided in the main report. The findings of this project, which was undertaken rapidly in order to inform HTA research prioritization in the UK, provide a contemporary overview of the potential clinical role for PET in the NHS. Evidence is needed that using PET as a diagnostic